HRAS mutations in non-HNSCC cancer cell lines have previously shown sensitization to MAPK inhibitors.13 In cell line 10336, many inhibitors, including trametinib, resulted in increases in metabolic rate, highlighting the importance of stratifying patient populations by drug sensitivity. This evidence concerns the gene HRAS and head and neck squamous cell carcinoma.